

Inflammatory Disease Pipeline

			Pre-Clinical	Phase 1	Phase 2	Phase 3	Filed	Updates since Q3'20
Inflammatory Disease	Filgotinib JAK-1 inhibitor (GS-6034)	Ulcerative colitis	▲	MAA Filed				MAA filed
	Filgotinib JAK-1 inhibitor (GS-6034)	Crohn's Disease						
	Filgotinib JAK-1 inhibitor (GS-6034)	Psoriatic arthritis	▲					Removed from pipeline
	Filgotinib JAK-1 inhibitor (GS-6034)	Ankylosing spondylitis	▲					Removed from pipeline
	Filgotinib JAK-1 inhibitor (GS-6034)	Uveitis	▲					Removed from pipeline
	TPL2 inhibitor (GS-4875)	Ulcerative colitis	▲					Removed from pipeline
	TPL2 inhibitor (GS-5290)	Inflammatory Bowel Disease	★					New
	IRAK4 inhibitor (GS-5718)	Inflammatory Bowel Disease						
	IRAK4 inhibitor (GS-5718)	Lupus	★					New
	Tirabrutintib BTK inhibitor (GS-4059)	CSU	★					New
	α4β7 inhibitor (GS-1427)	Inflammatory Bowel Disease						
	Small molecule inhibitor (neutrophil target)	Inflammatory Diseases						
	Small molecule inhibitor (innate immunity target)	Inflammatory Diseases						
Fibrotic Disease	Cilofexor FXR agonist (GS-9674)	PSC						
	Ziritaxestat ATX inhibitor (GLPG-1690)	IPF						
	Cilofexor / firsocostat combination	NASH						
	Selonsertib ASK1 inhibitor (GS-4997)	DKD						
	Ziritaxestat ATX inhibitor (GLPG-1690)	Systemic Sclerosis	▲					Removed from pipeline
Options	Galapagos	Inflammatory and Fibrosis Diseases		8 clinical stage programs				
	Galapagos	Inflammatory and Fibrosis Diseases		Multiple pre-clinical stage programs				

★ New listing since Q3'20 ▲ Change since Q3'20

